Skip to content

Lu Hong Granule in management of Heart Failure in Coronary Artery Disease patients: A randomized multi-center study.

Integrative Medicine program optimization study in coronary artery disease with heart failure

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003242
Enrollment
Unknown
Registered
2013-05-07
Start date
2013-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease with heart failure

Interventions

Treatment group:standard treatment of heart failure+Lu Hong Granule
comparison group:standard treatment of heart failure

Sponsors

Shuguang hospital affiliated to Shanghai university of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Aged from 18-85 with no sex limitation; diagnosis in coronary artery disease with left ventricular dysfunction; Lu Hong Granule treatment group should with TCM diagosis yang deficient and blood stasis; in class II-IV heart failure diagosis by New York Heart Association.

Exclusion criteria

Exclusion criteria: persistant severe angina (CCS Class IV); undertaking CABG or PCI surgery during the trial; kidney failure with SCr>1.5*ULN; severe liver disease or abnormal in liver biomarks(ALT, AST or TBil>2* ULN); any other severe disease or situation like malignant tumor; undertaking another clinical trial; pregnant woman or preparing to pregnant; researchers think not being suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
all-cause mortality;Nonfatal myocardial infarction;Nonfatal stroke;Intervention or surgery therapy caused by ACS or angina;Worsening heart failure hospitalization;carotid artery ultrasound;cardiac ultrasound;BNP;Cardiac function;TCM symptoms evaluation;Efficacy evaluation;

Secondary

MeasureTime frame
blood routine test;urine routine test;6-minute walk test;Hypersensitivity CRP;blood routine tests;Liver function;Renal function;electrocardiogram;electrolyte;TNI;blood lipids;Quality of life survey;Medication adherence survey;blood glucose;

Countries

China

Contacts

Public ContactWang Xiao-long
wxlqy0214@163.com+86 13501991450

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026